This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ACACA · Western blot design guide
ACACA Western Blot Planning Guide
Plan a ACACA Western blot around the catalog-observed 265.6 kDa band, image-backed A01802-2 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
ACACA Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 265.6 kDa observed | |
| Observed band | 265.6 kDa observed | |
| Gel | 4-12% gradient | |
| Positive control | Adrenal gland | |
| Negative control | Bone marrow |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 265.6 kDa |
| ⓘ | Localization | Cytoplasm, cytosol |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated ACACA Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Adrenal gland |
| Gel % | 4-12% gradient |
| Load | 20-30 µg total protein per lane |
| Transfer | Wet/tank, extended transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A01802-2 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected ACACA Western Blot Band Size?
Use the product-observed 265.6 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 265.6 kDa | Matches the authoritative product WB observation. |
| 265.6 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected ACACA appearancePlan around 265.6 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 265.6 kDa; use this as the primary experimental expectation. |
| Calculated mass | 265.6 kDa from UniProt Q13085; retain as context. |
| Gel selection | 4-12% gradient; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A01802-2. |
| Situation | Likely cause | Next action |
|---|---|---|
| 265.6 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing ACACA band
A01802-2 · ACACA
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for ACACA Western blot
🧪Use Adrenal gland as the first positive-control candidate and retain an orthogonal negative control.
Positive control: Adrenal gland (High)
Negative control: Bone marrow (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for ACACA
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Reported tissue cells | High | Protein (HPA) | HPA → |
| Colon | Reported tissue cells | High | Protein (HPA) | HPA → |
| Bronchus | Reported tissue cells | High | Protein (HPA) | HPA → |
| Duodenum | Reported tissue cells | High | Protein (HPA) | HPA → |
Section 3
Advanced ACACA Western Blot Tips
Deeper troubleshooting and optimisation questions for ACACA, answered from its protein features.
Which band should guide the blot?
Use 265.6 kDa, the observation attached to the authoritative A01802-2 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 265.6 kDa expectation.
Which positive control should I start with?
Start with Adrenal gland, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Bone marrow as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 4-12% gradient consistently across the quick facts, protocol table, and poster.
What transfer method to use for ACACA Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A01802-2 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
ACACA Western Blot Reagents
Human/Mouse/Rat-reactive ACACA Western blot reagents with authoritative product imagery.
Real WB data
Anti-ACACA Antibody Picoband®
Cat # A01802-2
Real WB data
Anti-ACACA Antibody Picoband®
Cat # A01802-3
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt Q13085
- Human Protein Atlas — ACACA
- A01802-2 product record
- PMC12291313 — ACACA depletion activates the cPLA2-arachidonic acid-NF-κB axis to drive inflammatory reprogramming in androgen receptor-independent prostate cancer (Cell communication and signaling : CCS, 2025)
- PMC7738814 — Down-regulation of ACACA suppresses the malignant progression of Prostate Cancer through inhibiting mitochondrial potential (Journal of Cancer, 2021)